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The subject of my discussion is prenatal diagnosis of genetic disorders of a metabolic rather
than a chromosomal nature. Whereas the chromosomal defects are the result of either the transmission of a translocated chromosome from a single
parent to its offspring or an error in meiosis or
mitosis, almost all metabolic disorders are inherited
in an autosomal recessive fashion. Therefore, except in rare instances, the only clue to the possible
presence of an inborn error of metabolism (IEM)
in the fetus is that a previous child of the parents
has had the disorder. This history identifies both
mother and father as heterozygotes for the deleterious gene and thus forewarns that each subsequent
pregnancy is at a 1 : 4 risk of yielding the disorder
again. By studying the amniotic fluid of the at-risk
fetus, it is now possible to determine if the disorder
is present, and if so, to prevent its occurrence by
therapeutic abortion. My main purpose is first to
review the status of the art of amniocentesis and
biochemical analysis of the material thus obtained,
and then to examine the impact this procedure will
have on the incidence and management of the
IEM.
Amniocentesis in the second half of pregnancy
for the diagnosis and treatment of erythroblastosis
has been widely used for almost two decades with a
minimum of morbidity or mortality to the mother
or fetus . Theoretical risks of the procedure (fetal
abortion, puncture, or induced malformation, and
maternal bleeding, infection, or sensitization) had
not been reported when the accumulated experience
of 500 amniocenteses during the first half of pregnancy were reviewed one year ago (Nadler: BD,
1971). Prior to the 10th week of gestation there are
less than 30 cc. of amniotic fluid present, and the
uterus has not yet risen outside of the pelvis. Because of these facts, a transabdominal approach at
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this time is usually unsuccessful and the transvaginal
route is attendant with a high risk of complications
(especially abortion) (Fuchs, 1971). For these reasons the procedure is usually withheld until the
13th to 14th week, at which time approximately
100-120 cc. of amniotic fluid are present, and the
uterus can easily be positioned to the anterior midline by bimanual examinations. Most investigators
do not use placental localization, and they accomplish the procedure on an out-patient basis. In the
combined experience of four investigators only
11 % of 353 taps had to be repeated in order to get
adequate material; initial failure in the majority of
cases was due to contamination by gross blood
(Nadler: BD, 1971).
Almost all of the cells present in the amniotic
fluid are of fetal origin (either from amnion or
skin), and some are viable. If the removed fluid is
placed in a siliconized container, the cells will not
adhere to the walls, and they can be shipped by
mail over a 48-hour period or stored overnight in a
refrigerator. When these cells are isolated from the
amniotic fluid by centrifugation and placed in
appropriate tissue culture media, their growth and
multiplication rapidly ensues. After. two subcultures
and a total of four weeks of growth, hopefully a
sufficient number of cells is present for analysis.
Depending upon the disorder, the biochemical test
performed is the measurement of either specific
enzyme activity or of possible accumulation of a
substance (such as mucopolysaccharides). Unfortunately, tissue sufficient in quantity to perform the
desired test can be obtained only 75-90% of the
time (Nadler: SM!, 1971); with chromosomal
studies, success rates of 95-99% have been
achieved (Nadler: BD, 1971; SM!, 1971).
The major premise utilized with this procedure
is that these cultured amniotic cells accurately reflect the specific characteristics of the disorder in
question. Previous studies of skin fibroblast cultures
have proven that these cells do reflect the deficient
state of the whole organism in most disorders.
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When the amniotic fluid cells are first removed
they have the morphological appearance of epithelial cells, but in culture they take on the biochemical and morphological characteristics of fibroblasts. However, many factors affecting the enzyme
activity of these cells must be considered before
proper interpretation of results is possible (for
example, stage of gestation, stage of growth of cells,
degree of cell confluency). If one also remembers
that these techniques must be refined to the point
where the investigator can accurately differentiate
the heterozygote from the homozygote, then hopefully he is left with the highest regard for the
complexities of this diagnostic procedure.
In addition to the use of cultured amniotic
fluid cells, biochemical analysis of uncultured amniotic fluid cells or of the amniotic fluid itself may
provide sufficient information to make an accurate
prenatal diagnosis. Although presently less than a
half-dozen disorders can be detected by these
methods (Nadler: BD, 1971), we hope further refinements will serve to increase this number, because such progress would obviate the minimum
4-week delay required to culture. Using cultured
cells to establish the diagnosis leaves only a precious week or two to effect any needed abortion,
as there are substantial medical, if not legal, restrictions to performing a therapeutic abortion
much after the 20th gestational week.
Now that we have briefly described the capabilities and limitations of the procedure itself, let
us examine how its usage can affect our present
management of the IEM. The various modalites
of treatment presently utilized (for example, limiting
substrate, providing deficient end product), for the
most part, do not attack the basic problem-that
of decreased enzyme activity. Recently, there has
been much discussion regarding the feasibility of
gene therapy, that is, the isolation of some of the
patient's somatic cells, the alteration of their genetic
endowment in vitro, and their replacement in the
individual. Other possible methods of providing the
deficient enzyme include organ transplantation or
specific enzyme replacement, but none of these approaches (particularly gene therapy) appears feasible in the next few years.
The only preventive measures available in the
past were genetic counseling and abortion of male
fetuses of mothers carrying a serious sex-linked
disease such as muscular dystrophy (the sex of the
fetus can be fairly accurately established by a study
of the sex chromatin status of uncultured or cultured amniotic fluid cells). Genetic counseling is a

good preventive measure because the majority of
parents given a 1 : 4 recurrence risk will be deterred from future pregnancies, especially where
the disorder is lethal or uncontrollable and where
there are already one or more normal children in
the family. But what of the parents whose first
child has a serious inborn error of metabolism and
who wish a normal child but are rightfully fearful
of the 1 :4 recurrence risk? This is where the amniocentesis and subsequent determination of the
specific enzyme content of fetal cells is especially
useful. I presently have two sets of young parents,
each with an infant with Hurler's syndrome, who
wish to have their first normal child. Only 3-4
laboratories in the country have developed the necessary techniques for the in utero diagnosis of this
condition. Should one of these laboratories agree
to monitor the pregnancy, and if the parents consent to an abortion if studies show an involved
fetus, either the amniotic fluid (with the cells) or
already cultured cells would be mailed to that laboratory.
At the present time there are less than twelve
laboratories active in the prenatal diagnosis of the
IEM-most, if not all, of these operate in a research rather than service capacity. A coordination
of these various centers is needed because no one
laboratory can perform all the available tests. As
of one year ago there had been less than 25 therapeutic abortions performed in the United States
for proven fetal metabolic disorders (Nadler: BD,
1971). This number would have been much higher
had the biochemical determinations been more
readily available.
What effect will this development have in reducing the actual number of infants born with
metabolic disorders? One should remember that at
present we must have an index case before knowing that we should monitor future pregnancies.
Therefore, the birth of a majority of patients with
IEM will not be prevented. Making the assumption that the goal of a family is to have two normal
children, Motulsky has calculated that performing
therapeutic abortions on all fetuses found to have a
metabolic disorder (after one sibling involvement)
will only reduce the incidence of that disorder by
12.5-34% (Motulsky, 1971).
In order to substantially reduce the incidence
of these disorders we would need to identify which
parent pairs are heterozygotic for the same deleterious gene before the delivery of their first affected
child. It would be impractical to screen all prospective parents for heterozygosity for most of the
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over 150 autosomal recessive IEM, because either
the disease is so rare, or the test is too difficult to
perform on a mass basis. However, it is presently
feasible to screen certain high-risk groups for certain disorders-for instance, sickle trait testing for
Blacks and the measurement of serum hexosaminidase A (for Gaucher's disease) in Ashkenazi Jews.
Also, because of its prevalence in Caucasians, mass
screening for the gene for cystic fibrosis should be
performed once a simple reliable test is developed.
Many ethical, moral, legal, and theological
issues are raised with our ability to define the
metabolic status of the fetus. Time does not permit
any in-depth discussion of these matters, but Jet me
pose two questions as examples:
1. Should one abort a fetus who has galacto-

semia, pyridoxine-responsive homocystinuria, or phenylketonuria? These disorders
are severe if untreated but the prognosis is
good with dietary restriction or vitamin
supplementation.
2. Should one induce an abortion where only
one of nonidentical twins has an untreatable metabolic disorder?
At present it is felt that the final decision must be
left to the parents, with the obstetrician and geneticist providing informed but impartial counsel. Per-
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haps shortly, each center involved in prenatal diagnosis will establish a board of physicians ,and lay
people to reach a consensus i11 each given case.
In summary; it is now theoretically possible to
diagnose approximately 40 different inbor,n errors
of inetabolism in a fetus early enough in gestation
to perform a therapeutic abortion. However, most
of these disorders are extremely rare, the techniques laboriOus, and diagnosis possible ~nly . after
one sibling is already involved. For now, higher
priority should be given to the development of
procedures for massive heterozygote screening and
iptrauterine diagnosis .of more common recessive
diseases such as cystic fibrosis and sickle cell anemia.
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